--- title: "20:10 ETAscletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)" type: "News" locale: "en" url: "https://longbridge.com/en/news/285284628.md" description: "Ascletis Pharma Inc. will present multiple programs at the 33rd European Congress on Obesity (ECO 2026) in Istanbul from May 12-15, 2026. Key presentations include Phase I data on ASC47, showing up to 111.8% greater weight loss when combined with semaglutide, and preclinical data on ASC36, demonstrating a 32-day half-life and significant weight loss in animal models. The company focuses on developing innovative therapeutics for metabolic diseases and is listed on the Hong Kong Stock Exchange." datetime: "2026-05-06T00:10:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285284628.md) - [en](https://longbridge.com/en/news/285284628.md) - [zh-HK](https://longbridge.com/zh-HK/news/285284628.md) --- # 20:10 ETAscletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026) , /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the 33rd European Congress on Obesity (ECO 2026), taking place May 12-15, 2026 in Istanbul, Türkiye. The presentations include a poster on the Phase I data of ASC47, an adipose-targeting thyroid hormone receptor beta (THRβ) agonist for muscle-preserving weight loss, which, in combination with semaglutide, demonstrated up to 111.8% greater relative weight loss in participants with obesity compared to semaglutide monotherapy, and a poster on the preclinical data of ASC36, a once-monthly next-generation amylin receptor agonist peptide, which demonstrated 32-day average observed half-life, 6-fold longer than petrelintide, in non-human primate (NHP) model and 91% more relative weight loss than petrelintide in diet-induced obese (DIO) rat model. **Presentation details** **Title:** ASC47 in Combination with Semaglutide Demonstrated Up to 111.8% Greater Relative Weight loss in Participants with Obesity Compared to Semaglutide Monotherapy **Session:** Track 4: Obesity Management and Intervention (PO4.264**)** **Date/Time:** Thursday, 14 May, 2026, 18:00–19:15 TRT **Title:** ASC36, a Once-Monthly Next-Generation Amylin Receptor Agonist Peptide, Demonstrated 32-day Average Observed Half-life, 6-fold Longer than Petrelintide, in NHP Model and 91% More Relative Weight Loss than Petrelintide in DIO Rat Model **Session:** Track 4: Obesity Management and Intervention (PO4.270**)** **Date/Time:** Thursday, 14 May, 2026, 18:00–19:15 TRT **Title:** ASC35, a Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist Peptide, Demonstrated 14-day Average Observed Half-life, 6-fold Longer than Tirzepatide, in NHP Model and 71% More Relative Weight Loss than Tirzepatide in DIO Mouse Model **Session:** Track 4: Obesity Management and Intervention (PO4.263**)** **Date/Time:** Thursday, 14 May, 2026, 18:00–19:15 TRT Additional information about the ECO 2026 is available at https://eco2026.org/. **About Ascletis Pharma Inc.** Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, ASC39, an eloralintide-like potent and amylin-selective oral small molecule amylin receptor agonist, and ASC30\_39 FDC, a fixed-dose combination (FDC) of ASC30 (GLP-1RA) and ASC39 (amylin RA), for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK). For more information, please visit www.ascletis.com. Contact： Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) \[email protected\] Ascletis Pharma Inc. PR and IR Teams +86-181-0650-9129 (China) \[email protected\] \[email protected\] SOURCE Ascletis Pharma Inc. ### Related Stocks - [01672.HK](https://longbridge.com/en/quote/01672.HK.md) ## Related News & Research - [20:10 ETAscletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions](https://longbridge.com/en/news/284662712.md) - [Assessing Ascletis Pharma (SEHK:1672) Valuation After ASC30_39 Obesity Candidate Advances Toward FDA IND Filing](https://longbridge.com/en/news/283226504.md) - [11:05 ETThe Church of Jesus Christ of Latter-day Saints Commits $25 Million to the UNICEF-led Child Nutrition Fund](https://longbridge.com/en/news/287088476.md) - [05:20 ETThrough the America's Most Artistic Kid Competition, Colossal Raises $1.6 Million While Celebrating the Next Gen of Creative Visionaries](https://longbridge.com/en/news/287037755.md) - [Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results | BLCO Stock News](https://longbridge.com/en/news/287118171.md)